Abstract

The present invention relates to inhibitors of ras farnesylation of the Formula I



Formula I

wherein:

R^1 is for example H and further values as defined in the specification; **R^2** is for example H and further values as defined in the specification; **R^3** is for example H or a substituent having values as defined in the specification; **p** is 0-3 in which R^3 values can be the same or different; **L** is a linking moiety for example -CH_2.NH- and further values as defined in the specification; **A** is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S; or a -S-S- dimer thereof when R^2=H; or a N-oxide or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation their use as therapeutic agents and pharmaceutical compositions containing them.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000